Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Resistance in Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On aspirin 81-325mg daily at time of enrollment~* Documented stable coronary artery disease or \> 6 months after coronary artery bypass grafting or interventional cardiac procedure~* Written informed consent~Exclusion Criteria:~* Pre-menopausal female~* Renal disease (creatinine \>= 2 mg/dl)~* Anemia (Hematocrit \< 30%)~* Thrombocytopenia (platelet count \< 135,000/ul)~* Use of NSAIDs or coxibs within the previous 2 weeks~* Concurrent use of other anti-platelet agents~* Uncontrolled hypertension (systolic BP \> 180 mmHg)~* Decompensated congestive heart failure~* Recent coronary syndrome (\< 6 months)~* History of significant GI bleeding

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enteric-coated aspirin (Type: EXPERIMENTAL): patients received enteric-coated aspirin 81 mg qd for 2 weeks
- Chewable aspirin (Type: ACTIVE_COMPARATOR): Patients received chewable aspirin 81 mg qd for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).